Douglas Jermasek
EVP, Corporate Strategy · Unicycive Therapeutics, Inc.
Individual
- 2025
- Jun 15, 2026
- 3
Other insiders active in the same sector
No other insider has filed at Douglas Jermasek's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- TCO GROUP HOLDINGS, L.P. - $92.50M in INNV purchases and sales in the last 12 months
- IGNITE AGGREGATOR LP - $92.50M in INNV purchases and sales in the last 12 months
- SUVRETTA CAPITAL MANAGEMENT, LLC - $90.98M in MANE purchases and sales in the last 12 months
- Steven Leonard Chapman - $89.87M in NTRA purchases and sales in the last 12 months
- Ugur Sahin - $84.23M in BNTX purchases and sales in the last 12 months
- Mark T. Bertolini - $82.60M in OSCR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Douglas Jermasek?
Douglas Jermasek is a corporate insider, tracked as EVP, Corporate Strategy of Unicycive Therapeutics, Inc. (UNCY). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Douglas Jermasek last file a Form 4?
The most recent primary Form 4 on record is dated 15 June 2026, one of 3 filings going back to 2025.